CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
omega-3 fatty acid +1 moredrug
Likely dose
omega-3 fatty acid 4gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00579436
NCT00579436N/ACompleted
CompareCT.gov

Effects of Fish Oils on Inflammation and Insulin Resistance

Philip Kern·interventional·Posted Dec 24, 2007·Updated May 16, 2018

In Brief

A clinical study evaluating omega-3 fatty acid and placebo for Metabolic Syndrome and Insulin Resistance. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Insulin Resistance
CountriesUnited States
CollaboratorsGlaxoSmithKline, National Institutes of Health (NIH), National Center for Research Resources (NCRR)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 24, 2007
Enrollment StartJan 1, 2007
Primary CompletionMar 27, 2013
Study CompletionJan 15, 2015
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 18.5 years ago

Interventions

omega-3 fatty aciddrug

4g of omega-3 fatty acid daily by mouth for 12 weeks.

placebodrug

4 inert capsules daily by mouth for 12 weeks.